Program
tradipitant
Also written as “Tradipitant”, “VLY-686” and “LY686017”.
Its studies are mostly in Motion Sickness · Gastroparesis · Dermatitis, Atopic · Pruritus · Nausea, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vanda Pharmaceuticals | 173 open or running | phase 3since Jun 13, 2018 | Aug 2, 2013 | Dec 1, 2026phase 3 · NCT07446439 |
| Eli Lilly | 20 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
Also a collaborator on its studies: cross-research-s-a.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Sep 12, 2005.
- Nov 17, 2015Phase 1 study in Healthy VolunteersVanda Pharmaceuticals · NCT02621385 · 24 enrolled · Switzerland
- Jan 6, 2016Phase 2 study in Dermatitis, AtopicVanda Pharmaceuticals · NCT02651714 · 168 enrolled · United States
- Nov 15, 2016Phase 2 study in GastroparesisVanda Pharmaceuticals · NCT02970968 · 152 enrolled · United States
- Jun 13, 2018Phase 3 study in Dermatitis, AtopicVanda Pharmaceuticals · NCT03568331 · 375 enrolled · United States
- Nov 28, 2018Phase 2 study in Motion SicknessVanda Pharmaceuticals · NCT03772340 · 126 enrolled · United States
- Jul 10, 2019Phase 3 study in GastroparesisVanda Pharmaceuticals · NCT04028492 · 979 enrolled · United States
- Oct 24, 2019Phase 3 study in Dermatitis, AtopicVanda Pharmaceuticals · NCT04140695 · 87 enrolled · United States
- Mar 26, 20202 phase 3 studiesVanda Pharmaceuticals · NCT04327661, NCT04326426
- Apr 13, 2021Phase 2 study in Healthy VolunteerVanda Pharmaceuticals · NCT04849559 · 27 enrolled · United States
- Mar 3, 2023Phase 3 study in Motion SicknessVanda Pharmaceuticals · NCT06138613 · 705 enrolled · United States
- Jun 5, 2023Phase 3 study in Motion SicknessVanda Pharmaceuticals · NCT05903924 · 316 enrolled · United States
- Apr 1, 2024Phase 3 study in GastroparesisVanda Pharmaceuticals · NCT06836557 · 17 enrolled · Belgium, Germany
- Jan 9, 2025Phase 2 study in ObesityVanda Pharmaceuticals · NCT06804603 · 124 enrolled · United States
- Feb 10, 2026Phase 3 study in NauseaVanda Pharmaceuticals · NCT07446439 · 280 planned · United States
Ahead
- Dec 1, 2026Primary completion: phase 3 study in NauseaVanda Pharmaceuticals · NCT07446439
- Sep 30, 2027Primary completion: phase 3 study in Motion SicknessVanda Pharmaceuticals · NCT06138613
TargetBeta
“An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist ”NCIt, by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aprepitantrule | Merck | phase 4 | 27 |
| elinzanetantrule | Bayer | phase 3 | 24 |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 2 |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07446439Nausea · United States | 3 | Recruiting | Vanda Pharmaceuticals | Dec 1, 2026 | 280 |
| NCT06804603Obesity · United States | 2 | Completed | Vanda Pharmaceuticals | Oct 6, 2025 | 124 |
| NCT06836557Gastroparesis · Belgium, Germany | 3 | Completed | Vanda Pharmaceuticals | Mar 30, 2026 | 17 |
| NCT05903924Motion Sickness · United States | 3 | Completed | Vanda Pharmaceuticals | Apr 6, 2024 | 316 |
| NCT06138613Motion Sickness · United States | 3 | Active, not recruiting | Vanda Pharmaceuticals | Sep 30, 2027 | 705 |
| NCT04849559Healthy Volunteer · United States | 2 | Completed | Vanda Pharmaceuticals | Sep 24, 2021 | 27 |
| NCT04327661Motion Sickness · United States | 3 | Completed | Vanda Pharmaceuticals | Apr 1, 2023 | 366 |
| NCT04326426Coronavirus Infections · United States | 3 | By invitation | Vanda Pharmaceuticals | Aug 1, 2020 | 300 |
| NCT04140695Dermatitis, Atopic · United States | 3 | Terminated | Vanda Pharmaceuticals | Oct 14, 2020 | 87 |
| NCT04028492Gastroparesis · United States | 3 | Completed | Vanda Pharmaceuticals | Feb 21, 2025 | 979 |
| NCT03772340Motion Sickness · United States | 2 | Completed | Vanda Pharmaceuticals | Jun 6, 2019 | 126 |
| NCT03568331Dermatitis, Atopic · United States | 3 | Completed | Vanda Pharmaceuticals | Dec 27, 2019 | 375 |
| NCT02970968Gastroparesis · United States | 2 | Completed | Vanda Pharmaceuticals | Nov 2018 | 152 |
| NCT02651714Dermatitis, Atopic · United States | 2 | Completed | Vanda Pharmaceuticals | Aug 4, 2017 | 168 |
| NCT02621385Healthy Volunteers · Switzerland | 1 | Completed | Vanda Pharmaceuticals | Feb 2016 | 24 |
| NCT02004041Pruritus · Germany | 2 | Completed | Vanda Pharmaceuticals | Feb 19, 2015 | 69 |
| NCT01919944Pruritus · Switzerland | 1 | Completed | Vanda Pharmaceuticals | Nov 2013 | 12 |
| NCT00805441Alcoholism · United States | 2 | Completed | Eli Lilly | Jul 2009 | 190 |
| NCT00191022Phobia, Social · United States | 2 | Completed | Eli Lilly | 185 |
How it is read
Names in the registry
- “Tradipitant”, 13 entries
- “VLY-686”, 2 entries
- “LY686017”, 2 entries
- “Open Label Tradipitant”, 1 entry
- “VLY-686 (Tradipitant)”, 1 entry
Conditions, from the studies’ own filings
- Motion Sickness, 4 studies
- Gastroparesis, 3 studies
- Dermatitis, Atopic, 3 studies
- Pruritus, 2 studies
- Nausea, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.